Comparative Benchmarking
In the context of the broader market, RVPH competes directly with industry leaders such as ATRA and GBIO. With a market capitalization of $34.06M, it holds a significant position in the sector. When comparing efficiency, RVPH's gross margin of N/A stands against ATRA's 96.67% and GBIO's 100.00%. Such benchmarking helps identify whether Reviva Pharmaceuticals Holdings Inc is trading at a premium or discount relative to its financial performance.
